Similar to BRCA1, a secondary mutation in BRCA2 has also been shown to restore the mutant BRCA2 reading frame into the wild-type reading frame in cisplatin-resistant ovarian cancer [39]. Here, BRCA2 is linked to ovarian carcinoma.